Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.
about
Optimal management of bone mineral disorders in chronic kidney disease and end stage renal diseaseLessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on DialysisLow lean tissue mass is an independent risk factor for mortality in patients with stages 4 and 5 non-dialysis chronic kidney diseaseLong-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.The use of cinacalcet hinders the diagnosis of parathyroid carcinoma in a chronic dialysis patient: a case reportA Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism.Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism.Managing hyperparathyroidism in hemodialysis: role of etelcalcetide.Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism.
P2860
Q28072340-93980231-D5E2-4763-8B9F-21F3540D04E9Q36687041-B7AE6D8F-71BC-4F72-BE99-39F54EEA2661Q37738198-CE331F84-5FD8-4784-96C8-505DC60BD89DQ38610957-0A660560-B2BD-4A6F-80B9-53017398B6D9Q38828618-182592F2-9F29-4A52-8462-6A6C775D40C4Q38828902-9335B9D7-4E3E-4889-A160-804AE07E0F8AQ42672060-3B51A4DB-61C4-4CD9-B897-61D9ECCD4ACCQ47102093-C6A78C88-057F-45D7-98AF-9A994D65FA26Q47549937-FB0AD8E2-7839-4AA5-ACEF-34653946A4CFQ50024790-9F5E04B8-0F4D-404B-A11F-8D2E08F1D192Q55109311-B757E824-8F6C-4580-AC4E-638A8803191D
P2860
Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Clinical and Practical Use of ...... Secondary Hyperparathyroidism.
@ast
Clinical and Practical Use of ...... Secondary Hyperparathyroidism.
@en
type
label
Clinical and Practical Use of ...... Secondary Hyperparathyroidism.
@ast
Clinical and Practical Use of ...... Secondary Hyperparathyroidism.
@en
prefLabel
Clinical and Practical Use of ...... Secondary Hyperparathyroidism.
@ast
Clinical and Practical Use of ...... Secondary Hyperparathyroidism.
@en
P2093
P2860
P356
P1476
Clinical and Practical Use of ...... Secondary Hyperparathyroidism
@en
P2093
César Ruiz-García
Iara daSilva
Jacqueline del Carpio
Jordi Bover
José Ballarín
Pablo Ureña
Patricia Lescano
P2860
P304
P356
10.2215/CJN.01760215
P577
2015-07-29T00:00:00Z